Gujarat Themis Biosyn LtdQ3 FY23Pharmaceuticals & Biotechnology

Gujarat Themis Biosyn Ltd

Q3 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 2

→Current sales closely match production; capacity utilization is above 100% due to prior inventory.
→Strong demand outlook for the rest of FY24; aiming to maintain or improve capacity utilization from last year's 75-80%.
→Expected revenue growth tied to full capacity utilization and new API block commissioning from December 2023.
→New API plant focusing on Rifapentine with flexible multi-purpose production capacity (~7 tons/month).
→Anticipate significant revenue increase once API revenues start, but exact growth magnitude is uncertain.
→Earlier guided 25-30% revenue growth in FY24 if 100% capacity utilization is sustained.
→Inventory normalized; no immediate benefit from inventory build-up expected going forward.
→Long-term growth boosted by expanding fermentation-based product portfolio and new CAPEX plans, which may exceed Rs. 200 crores.
→Market shifts like Rifapentine adoption and rifaximin patent expiry could positively impact volumes.

Category 3

→The company anticipates strong demand and expects better capacity utilization this year compared to the previous 75%-80% last year.
→Revenues for FY24 are expected to grow if 100% capacity utilization is achieved, targeting around Rs.190-200 crores.
→Growth is linked to selling what is produced, with no backlog inventory, implying stable real-time sales.
→API block commissioning by December 2023 is expected to generate incremental revenues starting FY25.
→Rifapentine production presents significant growth potential with promising pricing and market demand.
→EBITDA margins were impacted due to increased R&D and skilled workforce investments.
→EPS for Q2 FY24 was reported at Rs.8.63 per share; half-year EPS stands at Rs.20.83.
→CAPEX associated with growth is expected to increase (possibly doubling from Rs.200 crores), funded by internal accruals and debt-equity mix.
→R&D expenses may fluctuate, reflecting developmental activity levels.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Gujarat Themis Biosyn Ltd and 1,400+ other companies.

Yes

→Gujarat Themis Biosyn Limited is planning significant CAPEX over the next three years, likely increasing beyond the initially planned Rs. 200 crores.
→Funding for this CAPEX will be partially through internal accruals.
→The company will also pursue debt-equity financing but has not finalized the exact mix of debt or equity.
→A decision on the mode of funding (debt, equity, or mix) is expected within the next six to nine months.
→No specific mention of immediate fundraising via equity dilution; evaluations are ongoing.

→The transcript does not explicitly mention the exact current or expected order book or pending orders in numerical terms.
→Dr. Sachin Patel indicated strong demand currently with no backlog of inventory, implying orders are being fulfilled as produced.
→For Rifapentine, initial Indian government tenders indicate demand around 30-40 MT annually, possibly higher.
→The company anticipates growth if 100% capacity utilization is maintained, targeting Rs.190-200 crores top-line for FY24.
→Production matches sales currently; no carryover inventory suggests orders are being met promptly.
→New API capacity commissioning expected by December 2023 aims to support future order fulfillment and revenue growth.
→Demand for their products, including emerging ones like Rifapentine, is described as strong and solid for the near term.

Yes

→Phase-I CAPEX of around Rs. 80 crores is near completion with some additional minor spend expected until plant commissioning in December 2023.
→Construction of new API block and R&D block to be commissioned by December 2023.
→Additional fermentation capacity expansion underway, expected ready by 2025.
→Total CAPEX planned over three years initially estimated at Rs. 200 crores but now expected to be at least double that amount, possibly more.
→Funding will be through a mix of internal accruals and debt-equity options under consideration over the next 6-9 months.
→The company is applying for incentives from the Gujarat Government Biotechnology Promotion Board but not participating in the central government's PLI scheme.
→New facilities will comply with global regulatory norms targeting both domestic and export markets.

How does Gujarat Themis Biosyn Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Gujarat Themis Biosyn Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Gujarat Themis Biosyn Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.